GSK disclosed detailed positive Phase 3 results for bepirovirsen, a chronic hepatitis B therapy it licensed from Ionis Pharmaceuticals. The company shared outcomes across two late-stage trials, with regulatory reviews underway in the US and three other markets. The updates add momentum to GSK’s antiviral franchise as it advances a therapy that targets viral replication drivers rather than aiming solely for immune modulation. Pending regulatory decisions will determine whether the data translate into approvals across multiple geographies. For clinicians and payers, the key next step is the agency review of trial endpoints and safety/tolerability characterization, including how the regimen fits alongside existing chronic hepatitis B standards of care.